natgillin/translations-raw huggingface dataset:
au Under behandling af hepatitis B eller C, anbefales det at udføre disse kontroller ved uge 1, 2, 4, 8, 12 og 16 samt hver anden måned derefter under hele behandlingen.
ed every other month, thereafter, throughout treatment.
Hvis ALAT blusser op under Viraferon- behandling til større end eller lig med 2 gange basisniveau, kan man fortsætte Viraferon - ere behandling med mindre der er tegn og symptomer på leversvigt.
If ALT flares during Viraferon therapy to greater than or equal to 2 times baseline, Viraferon therapy may be continued unless signs and symptoms of liver failure are observed.
ALAT, protrombintid, basisk fosfatase, albumin og bilirubin med to ugers interval. ng
ALT, prothrombin time, alkaline phosphatase, albumin and
Effekt på fertilitet:
ori Effect on fertility:
4. 5 Interaktion med andre lægemidler og andre former for interaktion læ
uth 4.5 Interaction with other medicinal products and other forms of interaction
Narkotika, hypnotika og sedativa skal indgives med forsigtighed samtidig med Viraferon. ke
Narcotics, hypnotics or sedatives must be administered with caution when used concomitantly with
Interaktioner mellem Viraferon og andre lægemidler er ikke fuldt vurderet.
Caution must be
Der bør udøves forsigtighed, når Viraferon indgives i kombination med andre potentielt myelosuppressive midler. r ik
ge exercised when administering Viraferon in combination with other potentially myelosuppressive agents.
Dette skal tages i betragtning ved samtidig behandling med præparater, der metaboliseres på denne måde, såsom xanthin- derivaterne theophyllin eller aminophyllin.
This must be considered during concomitant therapy lon with medicinal products metabolised by this route, such as the xanthine derivatives theophylline or aminophylline.
Ved samtidig behandling med xanthin- præparater bør serum- theophyllin- niveau te
During concomitant therapy with xanthine agents, serum theophylline levels must be monitored and dosage adjusted if necessary. no
Lungeinfiltrat, pneumonitis og pneumonia, undertiden resulterende i dødsfald, er sjældent blevet dle
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with Viraferon.
4. 4). mi
These symptoms have been reported more frequently when shosaikoto, a Chinese herbal medicine, is administered concomitantly with interferon alpha (see section 4.4). t uc
(Se tillige ribavirin produktresume hvis Viraferon skal indgives i kombination med ribavirin hos patienter med kronisk hepatitis C). ge
(Also see ribavirin SPC if Viraferon is to be administered in combination with ribavirin in patients with chronic hepatitis C). rod
4. 6 Graviditet og amning Læ
4.6 Pregnancy and lactation lp
Nedsatte serum østradiol og progesteron koncentrationer har været rapporteret hos kvinder behandlet med human leukocyt- interferon.
Decreased serum estradiol and progesterone concentrations have been reported in women treated with human leukocyte interferon. na
5. 3).
There are no adequate data from the use of interferon alfa-2b in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).
Den potentielle risiko for mennesker er ukendt.
Viraferon is to be i dic
Viraferon må kun anvendes under graviditet, hvis den mulige gavn berettiger den potentielle risiko for fosteret.
used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
alg Det vides ikke, om indholdsstofferne af præparatet udskilles i modermælk.
It is not known whether the components of this medicinal product are excreted in human milk.
Af hensyn til muligheden for bivirkninger hos de ammede børn, bør amning afbrydes før påbegyndelse af behandling.
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of Me
s Kombinationsbehandling med ribavirin:
Combination therapy with ribavirin:
Ribavirin forårsager alvorlige fosterskader ved anvendelse
Ribavirin causes serious birth defects when administered during pregnancy.
til under graviditet.
Ribavirin therapy is contraindicated in women who are pregnant.
Ribavirin behandling er kontraindiceret hos kvinder, der er gravide.
Extreme care must be taken to avoid pregnancy in female patients or in partners of male patients taking Viraferon in combination with ribavirin.
Den yderste forsigtighed skal udvises for at undgå graviditet hos kvindelige patienter eller hos partnere af mandlige patienter, der får Viraferon i kombination med ribavirin.
Females of childbearing potential and their partners must each use an effective contraceptive during treatment and for 4 months after treatment has been concluded.
Fertile kvinder og deres partnere skal begge
Male patients and their female partners must
Mandlige patienter og deres kvindelige partnere skal begge anvende en effektiv antikonception under behandling og i 7 måneder efter behandlingen er afsluttet (Se Ribavirin SPC).
8 each use an effective contraceptive during treatment and for 7 months after treatment has been concluded (see ribavirin SPC).
is 4. 7 Virkning på evnen til at føre motorkøretøj eller betjene maskiner
4.7 Effects on ability to drive and use machines
tor Patienter bør informeres om, at de kan udvikle træthed, døsighed eller konfusion under behandling med Viraferon, og derfor anbefales det, at de undgår at føre bil og betjene maskiner.
Patients are to be advised that they may develop fatigue, somnolence, or confusion during treatment with Viraferon, and therefore it is recommended that they avoid driving or operating machinery.
au 4. 8 Bivirkninger
ed 4.8 Undesirable effects
Se ribavirin produktresume vedrørende ribavirinrelaterede bivirkninger, hvis Viraferon skal indgives ere sammen med ribavirin til patienter med kronisk hepatitis C.
s See ribavirin SPC for ribavirin-related undesirable effects if Viraferon is to be administered in combination
I kliniske undersøgelser foretaget i en lang række indikationer og i et bredt dosisområde (fra 6 MIE/ m2/ uge ved hårcelleleukæmi op til 100 MIE/ m2/ uge ved melanom) var de mest almindeligt ng
In clinical trials conducted in a broad range of indications and at a wide range of doses (from 6 MIU/ m2/ week
rapporterede bivirkninger feber, træthed, hovedpine og myalgi.
uth in hairy cell leukaemia up to 100 MIU/ m2/ week in melanoma), the most commonly reported undesirable effects were fever, fatigue, headache and myalgia.
Feber og træthed var ofte reversible inden for 72 timer efter afbrydelse eller ophør af behandlingen. læ
Fever and fatigue were often reversible within 72 hours of interruption or cessation of treatment.
I kliniske undersøgelser udført hos patienter med hepatitis C, blev forsøgspersonerne behandlet med Viraferon alene eller i kombination med ribavirin i et år.
ra In clinical trials conducted in the hepatitis C population, patients were treated with Viraferon alone or in combination with ribavirin for one year.
Alle patienter i disse undersøgelser fik 3 MIE Viraferon tre gange om ugen.
All patients in these trials received 3 MIU of Viraferon three times a
Indenfor r ik
The adverse reactions listed in Table 1 are based on experience from clinical trials and post-marketing.
Inden for hver enkelt frekvensgruppe te
Within the organ lon system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/ 10); common (≥ 1/ 100, < 1/ 10); rarely (≥ 1/ 10,000, < 1/ 1,000); very rarely (< 1/ 10,000); not known.
er bivirkningerne opstillet efter faldende alvorlighed.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. no
Bivirkninger rapporteret ved kliniske undersøgelser eller efter markedsføring af Viraferon alene dle
Adverse reactions reported during clinical trials or following the marketing use of Viraferon alone or in combination with ribavirin System Organ Class
eller i kombination med ribavirin Systemorganklasser Infektioner og parasitære sygdomme mi
t
Sjælden: ge
Rarely:
Pharyngitis *, viral infektion * Bronkitis, sinuitis, herpes simplex (resistent), rhinitis Lungebetændelse§
Pharyngitis*, infection viral* Bronchitis, sinusitis, herpes simplex (resistance), rhinitis Pneumonia§
Læ
Common:
Leukopeni
lp
§
na
Thrombocytopeni, lymphadenopati, lymphopeni Aplastisk anæmi Pure red cell aplasi, idiopatisk thrombocytopenisk purpura, thrombotisk thrombocytopenisk purpura
Aplastic anaemia Pure red cell aplasia, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura
Meget sjælden:
Immune system disorders§ Very rarely:
Sarcoidose, forværring af sarcoidose Systemisk lupus erythematose, vaskulitis, reumatoid arthritis (ny eller forværret), Vogt- Koyanagi- Harada syndrom, akutte overfølsomhedsreaktioner inklusive nældefeber, angioødem,
i
alg bronkokonstriktion, anafylakse§ Det endokrine system Almindelig:
Sarcoidosis, exacerbation of sarcoidosis Systemic lupus erythematosus, vasculitis, rheumatoid
Hypothyroidisme§, hyperthyroidisme§
arthritis (new or aggravated), Vogt-Koyanagi-Harada syndrome, acute hypersensitivity reactions including urticaria, angioedema, bronchoconstriction, anaphylaxis§ Me
s Meget sjælden:
Very rarely:
Diabetes, forværret diabetes
Hypothyroidism§, hyperthyroidism§ Diabetes, aggravated diabetes
til Meget almindelig:
Very common:
Meget sjælden:
Very rarely: § Psychiatric disorders
t ere Psykiske forstyrrelser§ Meget almindelig:
9 Very common:
is Sjælden:
Rarely:
Selvmordstanker Selvmord, selvmordsforsøg, aggressiv adfærd (nogle gange
Confusion, sleep disorder, libido decreased Suicide ideation Suicide, suicide attempts, aggressive behaviour (sometimes directed against others), psychosis including hallucinations
tor rettet mod andre), psykose inklusive hallucinationer Ikke kendt:
Not known:
au Meget almindelig:
ed Nervous system disorders§ Very common:
Svimmelhed, hovedpine, koncentrationsbesvær, mundtørhed Tremor, paresthesi, hypoesthesi, migræne, rødmen, søvnighed, smagsforstyrrelser ere
Dizziness, headache, concentration impaired, mouth dry Tremor, paresthesia, hypoesthesia, migraine, flushing,
Meget sjælden:
ori Very rarely:
Cerebrovaskulær blødning, cerebrovaskulær iskæmi, kramper, bevidsthedsforstyrrelse, encephalopati, neuropati, polyneuropati
Cerebrovascular haemorrhage, cerbrovascular ischaemia, seizure, impaired consciousness, encephalopathy, neuropathy, polyneuropathy
Ikke kendt:
uth Not known:
Øjne Meget almindelig:
Very common:
Almindelig:
ra Common:
Retinal blødning§, retinopatier (inklusive makulært ødem), retinal arterie - eller veneobstruktion§, optisk neuritis,
Retinal haemorrhages§, retinopathies (including macular
papilødem, tab af synsskarphed eller synsfelt, slørede pletter§ Øre og labyrint r ik
ge oedema), retinal artery or vein obstruction§, optic neuritis, papilloedema, loss of visual acuity or visual field, cotton- wool spots§ lon Ear and labyrinth Common:
Vertigo, tinnitus Tab af hørelse, høreforstyrrelser
Vertigo, tinnitus Hearing loss, hearing disorder no
Meget sjælden: dle
Very rarely:
Palpitation, tachycardi Cardiomyopati Myocardieinfarkt, hjerteiskæmi
Palpitation, tachycardia Cardiomyopathy Myocardial infarction, cardiac ischaemia
Vaskulære sygdomme
uc
Almindelig: mi
Vascular disorders Common:
Hypertension
Hypertension Peripheral ischaemia, hypotension§
Luftveje, thorax og mediastinum ge
Respiratory, thoracic and mediastinal disorders Very common:
Perifer iskæmi, hypotension§
Dyspnoea*, coughing*
Dyspnø *, hoste * Epistaxis, respiratorisk forstyrrelse, forstoppet næse, rhinorrhea, hoste uden slim
Epistaxis, respiratory disorder, nasal congestion, rhinorrhea, cough nonproductive
Mave- tarmkanalen
Gastrointestinal disorders Very common:
Lungeinfiltrationer§, lungebetændelse§
Nausea/ vomiting, abdominal pain, diarrhoea, stomatitis,
Meget almindelig:
dyspepsia dic
Meget sjælden:
Me
Pancreatitis, iskæmisk colitis, ulcerativ colitis, blødning af tandkød
Pancreatitis, ischaemic colitis, ulcerative colitis, gingival
Ikke kendt:
bleeding Not known:
alg Almindelig:
Common:
s Meget almindelig:
Very common:
Alopeci, pruritus *, tør hud *, udslæt *, øget svedtendens Psoriasis (ny eller forværret) §, maculopapulært udslæt,
Alopecia, pruritus*, skin dry*, rash*, sweating increased Psoriasis (new or aggravated)§, rash maculopapular, rash
til erytematøst udslæt, eksem, erytem, hudlidelser Meget sjælden:
10 erythematous, eczema, erythema, skin disorder Very rarely:
t ere Knogler, led, muskler og bindevæv Meget almindelig:
Very common:
Meget sjælden:
ed Very rarely:
Myalgi, arthralgi, smerter i bevægeapparatet Arthritis Rhabdomyolyse, myositis, benkramper, rygsmerte
Rhabdomyolysis, myositis, leg cramps, back pain
is Nyrer og urinveje Almindelig:
Common:
tor Meget sjælden:
s Very rarely:
Almindelig:
ori Reproductive system and breast disorders Common:
Amenorré, brystsmerte, dysmenore, menoragi,
Amenorrhea, breast pain, dysmenorrhea, menorrhagia,
au menstruationsforstyrrelser, vaginale lidelser Almene symptomer og reaktioner på administrationsstedet ere Meget almindelig:
uth menstrual disorder, vaginal disorder General disorders and administration site conditions
Almindelig:
ra Very common:
Smerte på injektionsstedet
Injection site inflammation, injection site reaction*, fatigue, rigors, fever§, flu-like symptoms§, asthenia, irritability, chest pain, malaise
ng
ge Common:
Nekrose på injektionsstedet, ansigtsødem
Injection site pain Injection site necrosis, face oedema lon
4. 4 ke
*These events were only common with Viraferon alone § See section 4.4 no
Disse bivirkninger er også rapporteret med Viraferon alene. r ik
These undesirable effects have also been reported with Viraferon alone.
Kardiovaskulære (CV) bivirkninger, specielt arytmi, syntes for det meste at være indbyrdes forbundet med tidligere CV sygdom og tidligere behandling med kardiotoksiske stoffer (se pkt.
Cardiovascular (CVS) adverse events, particularly arrhythmia, appeared to be correlated mostly with pre- t
Kardiomyopati, som kan være reversibel efter seponering af interferon alfa, er blevet rapporteret sjældent hos patienter uden tidligere observeret hjertesygdom (se pkt.
existing CVS disease and prior therapy with cardiotoxic agents (see section 4.4).
4. 4). te
Cardiomyopathy, that may uc
Mange forskellige autoimmune og immunmedierede sygdomme er blevet rapporteret med alfa - interferoner inklusive thyroidealidelser, systemisk lupus erythematosus, reumatoid athritis (ny eller dle
be reversible upon discontinuation of interferon alpha, has been reported rarely in patients without prior evidence of cardiac disease (see section 4.4). rod
forværret), idiopatisk og thrombotisk thrombocytopenisk purpura, vasculitis, neuropatier inklusive mononeuropatier (se også pkt.
A wide variety of autoimmune and immune-mediated disorders have been reported with alpha interferons including thyroid disorders, systemic lupus erythematosus, rheumatoid arthritis (new or aggravated), idiopathic and thrombotic thrombocytopenic purpura, vasculitis, neuropathies including mononeuropathies lp
4. 4). mi
(see also section 4.4).
Klinisk signifikante laboratorieafvigelser er hyppigst set med doser større end 10 millioner IE dagligt og omfatter reduktion i antal af granulocytter og hvide blodlegemer, nedsat hæmoglobinniveau og ge
Clinically significant laboratory abnormalities, most frequently occurring at doses greater than 10 million IU na
trombocyttal, øgning i basisk fosfatase, LDH, serum- kreatinin og serum- urinstof.
daily, include reduction in granulocyte and white blood cell counts; decreases in haemoglobin level and platelet count; increases in alkaline phosphatase, LDH, serum creatinine and serum urea nitrogen levels. i
Forøgelse i serum ALAT/ ASAT (SGPT/ SGOT) - koncentrationer er blevet observeret som en abnormitet hos nogle non - hepatitis personer samt hos nogle patienter med kronisk hepatitis B samtidig med udskillelse af viral Læ
Increase in serum ALT/ AST (SGPT/ SGOT) levels have been noted as an abnormality in some non-hepatitis dic
DNAp.
subjects and also in some patients with chronic hepatitis B coincident with clearance of viral DNAp.
4. 4.
Me
11 Børn
Paediatric population
Børn og unge - kronisk hepatitis C I kliniske undersøgelser med 118 børn og unge i alderen 3 til 16 år afbrød 6% behandling på grund af
Children and adolescents – Chronic Hepatitis C In clinical trials of 118 children or adolescents 3 to 16 years of age, 6% discontinued therapy due to adverse events.
Generelt svarede bivirkningsprofilen i den begrænsede undersøgte pædiatriske population til den profil, der er observeret hos voksne, selvom der er en specifik pædiatrisk bekymring vedrørende væksthæmning, da en procentvis formindsket højde (gennemsnitlig procentvis nedgang i
In general, the adverse event profile in the limited paediatric population studied was similar to that observed in adults, although there is a paediatric specific concern regarding growth inhibition as decrease in height (mean percentile decrease of growth velocity of 9%) and weight (mean percentile decrease of 13%)
s væksthastighed på 9%) og vægt (gennemsnitlig procentvis nedgang på 13%) blev observeret under behandling (se pkt.
11 percentile were observed during treatment (see section 4.4).
Derudover blev selvmordstanker eller - forsøg rapporteret hyppigere
Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6 month follow-up after treatment.
Derudover
As in adult patients, children and adolescents also experienced other psychiatric adverse events (e. g., depression, emotional lability, and somnolence) (see section 4.4).
t ere forekom lidelser på injektionsstedet, feber, anoreksi, opkastning og emotionel labilitet hyppigere hos børn og unge sammenlignet med voksne patienter.
In addition, injection site disorders, fever, anorexia, vomiting, and emotional lability occurred more frequently in children and adolescents compared to adult patients.
is De bivirkninger, der er listet i Tabel 2, er baseret på erfaringer fra kliniske undersøgelser med børn.
ed The adverse reactions listed in Table 2 are based on experience from paediatric clinical trials.
Følgende
Within the organ system classes, adverse reactions are listed under headings of frequency using the following
tor kategorier er anvendt: meget almindelig (≥1/ 10); almindelig (≥1/ 100, < 1/ 10).
Within each frequency grouping, undesirable
Inden for hver enkelt frekvensgruppe er bivirkningerne opstillet efter faldende alvorlighed.
ori effects are presented in order of decreasing seriousness.
Bivirkninger rapporteret som værende meget almindelige eller almindelige i kliniske undersøgelser hos børn Meget almindelig (≥1/ 10) - Almindelig (≥1/ 100, < 1/ 10) ere Systemorganklasser Infektioner og parasitære sygdomme
uth Very common (≥ 1/ 10) - Common (≥ 1/ 100, < 1/ 10) System Organ Class Infection and infestations
Meget almindelig:
ra Very common:
Svampeinfektion, bakteriel infektion, pulmonal infektion, otitis media, tand absces, herpes simplex, urinvejsinfektion, vaginitis, læ
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection,
gastroenteritis Benigne, maligne og uspecificerede tumorer (inkl. cyster og polypper) ke
ge vaginitis, gastroenteritis Neoplasms benign, malignant and unspecified (including lon cysts and polyps) Common:
Neoplasme (uspecificeret)
Neoplasm (unspecified) no
Anæmi, neutropeni Thrombocytopeni, lymphadenopati
Anaemia, neutropaenia Thrombocytopaenia, lymphadenopathy t
Meget almindelig: te
Very common:
Hypothyroidisme§,
Hypothyroidism§, uc
Metabolisme
Metabolism and nutrition
og ernæring dle
rod
Hyperthyroidisme§, virilisering
Hyperthyroidism§, virilism
Meget almindelig:
disorders Very common:
§
lp
Meget almindelig: mi
Very common:
Almindelig: ge
Common:
Selvmordstanker, aggressiv reaktion, forvirring, adfærdsforstyrrelser, agitation, søvngængeri, angst, nervøsitet,
Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour disorder, agitation, somnambulism, anxiety, nervousness, sleep
søvnforstyrrelser, unormale drømme, apati Nervesystemet§ Meget almindelig:
disorder, abnormal dreaming, apathy Nervous system disorders§ i
Læ
dic
Øjne
Eye disorders Me
Raynauds syndrome, rødmen, bleghed
Raynaud’ s disease, flushing, pallor
Dyspnø, takypnø, epistaxis, hoste, næseforstoppelse, næseirritation,
Dyspnoea, tachypnea, epistaxis, coughing, nasal congestion, nasal irritation, rhinorrhea, sneezing
alg næseflåd, nysen Mave- tarmkanalen Meget almindelig:
12 Very common:
s Almindelig:
Common:
til forstyrrelser, gastrointestinale forstyrrelser, forstoppelse, løs afføring, tandpine, tandproblemer Lever og galdeveje
Diarrhoea, vomiting, nausea, abdominal pain Mouth ulceration, stomatitis ulcerative, stomatitis, right upper quadrant pain, dyspepsia, glossitis, gastroesophogeal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder
t ere Almindelig:
Common:
Meget almindelig:
ed Skin and subcutaneous tissue disorders Very common:
Almindelig:
s Common:
Alopeci, udslæt Fotosensitivitets reaktioner, makulopapulært udslæt, eksem, akne,
Photosensitivity reaction, maculopapular rash, eczema, acne, skin
is hudlidelse, neglelidelse, pigmentforandringer, pruritus, tør hud, erythem, blå mærker, øget svedtendens
ori disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased Musculoskeletal and
tor Knogler, led, muskler og bindevæv Meget almindelig:
Renal and urinary disorders
au Nyrer og urinveje Almindelig:
ra Common:
Ufrivillig vandladning, vandladningsproblemer, urininkontinens ere
Enuresis, micturition disorder, urinary incontinence
Almindelig:
ge Common:
Kvinder: amenorré, menoragi, menstruations forstyrrelser, vaginale problemer ng
General disorders and administration site conditions
Mænd: testikelsmerter læ
Female: amenorrhea, menorrhagia, menstrual disorder, vaginal disorder Male: testicular pain lon
administartionsstedet Meget almindelig:
Very common:
Inflammation på injektionsstedet, reaktion på injektionsstedet, træthed, stivhed, feber§, influenzalignende symptomer§, utilpashed, irritabilitet
Injection site inflammation, injection site reaction, fatigue, rigors, no
Brystsmerte, asteni, ødem, smerte på injektionsstedet
Chest pain, asthenia, oedema, injection site pain t
Fald i væksthastighed (højde og/ eller vægtfald i forhold til alder) §
Growth rate decrease (height and/ or weight decrease for age)§ uc
Almindelig: te
Injury and poisoning Common:
4. 4 dle
§ See section 4.4
4. 9 Overdosering
4.9 Overdose lp
Som for ethvert farmakologisk aktivt stof er symptomatisk behandling med hyppig monitorering af mi
However, as for any pharmacologically active compound, symptomatic treatment with frequent monitoring of vital signs and close na
vitale tegn og tæt observation af patienten dog indiceret. ge
observation of the patient is indicated. i
FARMAKOLOGISKE EGENSKABER Læ
PHARMACOLOGICAL PROPERTIES dic
5. 1 Farmakodynamiske egenskaber
5.1 Pharmacodynamic properties Me
13 Viraferon er en steril, stabil, formulering af højt oprenset interferon alfa- 2b produceret ved rekombinant DNA- teknik.
Viraferon is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques.
alg Aktiviteten af Viraferon udtrykkes i IE, med 1 mg af rekombinant interferon alfa- 2b protein svarende til 2, 6 x 108 IE.
13 The activity of Viraferon is expressed in terms of IU, with 1 mg of recombinant interferon alfa-2b protein corresponding to 2.6 x l08 IU.
Internationale enheder fastsættes ved at sammenligne aktiviteten af rekombinant interferon
International Units are determined by comparison of the activity of the recombinant interferon alfa-2b with the activity of the international reference preparation of human leukocyte interferon established by the World Health Organisation.
til Interferoner er en familie af små proteinmolekyler med molekylevægte på cirka 15. 000- 21. 000 daltons.
The interferons are a family of small protein molecules with molecular weights of approximately 15,000 to 21,000 daltons.